BR112017009194A2 - tetra-hidropiranos substituídos e método de uso - Google Patents

tetra-hidropiranos substituídos e método de uso

Info

Publication number
BR112017009194A2
BR112017009194A2 BR112017009194A BR112017009194A BR112017009194A2 BR 112017009194 A2 BR112017009194 A2 BR 112017009194A2 BR 112017009194 A BR112017009194 A BR 112017009194A BR 112017009194 A BR112017009194 A BR 112017009194A BR 112017009194 A2 BR112017009194 A2 BR 112017009194A2
Authority
BR
Brazil
Prior art keywords
compounds
substituted tetrahydropyran
formula
methods
compositions
Prior art date
Application number
BR112017009194A
Other languages
English (en)
Inventor
Liu Bo
C Yeung Ming
R Kym Philip
B Searle Xenia
Wang Xueqing
Original Assignee
Abbvie Sarl
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl, Galapagos Nv filed Critical Abbvie Sarl
Publication of BR112017009194A2 publication Critical patent/BR112017009194A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo ?tetra-hidropiranos substituídos e método de uso? compostos da fórmula (i) (i) e sais farmaceuticamente aceitáveis ou formas radiomarcadas destes em que r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12 e m são como definidos na especificação, são úteis em tratar condições ou transtornos prevenidos por ou melhorados pela proteína reguladora de condutância transmembranar de fibrose cística (cftr). métodos para fabricar os compostos são descritos. também são descritos composições farmacêuticas de compostos da fórmula (i) e métodos para usar tais compostos e composições.
BR112017009194A 2014-10-31 2015-10-29 tetra-hidropiranos substituídos e método de uso BR112017009194A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073586P 2014-10-31 2014-10-31
PCT/US2015/058043 WO2016069891A1 (en) 2014-10-31 2015-10-29 Substituted tetrahydropyrans and method of use

Publications (1)

Publication Number Publication Date
BR112017009194A2 true BR112017009194A2 (pt) 2017-12-26

Family

ID=55851906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009194A BR112017009194A2 (pt) 2014-10-31 2015-10-29 tetra-hidropiranos substituídos e método de uso

Country Status (10)

Country Link
US (1) US9567322B2 (pt)
EP (1) EP3212184B1 (pt)
JP (1) JP6615213B2 (pt)
CN (1) CN107427490A (pt)
AU (1) AU2015339196A1 (pt)
BR (1) BR112017009194A2 (pt)
CA (1) CA2966023A1 (pt)
MX (1) MX2017005663A (pt)
TW (1) TW201625599A (pt)
WO (1) WO2016069891A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
SI3424534T1 (sl) 2014-04-15 2021-08-31 Vertex Pharmaceutical Incorporated Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
CA3001096A1 (en) 2015-10-09 2017-04-13 Abbvie S.A.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
BR112018007165A2 (pt) 2015-10-09 2019-01-22 AbbVie S.à.r.l. novos compostos para tratamento da fibrose cística
BR112018007145A2 (pt) 2015-10-09 2018-11-06 AbbVie S.à.r.l. ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
CN110483457A (zh) * 2018-05-14 2019-11-22 上海迈法生物科技有限公司 4-氨基四氢吡喃的一锅法合成工艺
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
NZ581419A (en) 2007-05-25 2012-05-25 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
CA2709301C (en) 2007-12-13 2016-05-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2008344922A1 (en) * 2007-12-18 2012-01-19 Glenmark Pharmaceuticals, S.A. Chromane derivatives as TRPV3 modulators
AU2009231993B2 (en) 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
BRPI0916713A2 (pt) * 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
JP5645835B2 (ja) 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｎ−（４−（７−アザビシクロ［２．２．１］ヘプタン−７−イル）−２−（トリフルオロメチル）フェニル）−４−オキソ−５−（トリフルオロメチル）−１，４−ジヒドロキノリン−３−カルボキサミドの固体形態
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011127290A2 (en) * 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2014160478A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
MX365950B (es) * 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Also Published As

Publication number Publication date
TW201625599A (zh) 2016-07-16
CN107427490A (zh) 2017-12-01
US9567322B2 (en) 2017-02-14
WO2016069891A1 (en) 2016-05-06
CA2966023A1 (en) 2016-05-06
EP3212184B1 (en) 2020-04-01
US20160122331A1 (en) 2016-05-05
EP3212184A4 (en) 2018-07-04
JP6615213B2 (ja) 2019-12-04
JP2017533277A (ja) 2017-11-09
AU2015339196A1 (en) 2017-05-11
MX2017005663A (es) 2018-03-01
EP3212184A1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
BR112017009194A2 (pt) tetra-hidropiranos substituídos e método de uso
CL2019001553A1 (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador.
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
CL2015002814A1 (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
PH12015501609A1 (en) Phenicol antibacterials
CL2015002897A1 (es) Inhibidores de bace1
MX2015009276A (es) Donadores de nitroxilo con indice terapeutico mejorado.
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016022046A2 (pt) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
BR112015022207A8 (pt) forma cristalina do composto i, formas cristalinas de sais do composto i e uso do composto i
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements